U.S. Software Stock News

NYSE:SAM
NYSE:SAMBeverage

Is Boston Beer Company (SAM) Priced Right After Mixed Craft And Hard Seltzer Demand Shifts

If you are wondering whether Boston Beer Company at around US$209.82 is a bargain or a value trap, you are not alone. That is exactly what this article tackles. The stock has returned 3.8% over the last 7 days and 3.3% over the last 30 days, although its 1 year return of a 19.0% decline and 5 year return of a 77.1% decline show a very different picture. Recent coverage has focused on how craft beer brands are competing for shelf space and how consumer tastes are shifting across beer, hard...
NYSE:ALSN
NYSE:ALSNMachinery

How Allison’s New Two-Unit Structure and Off-Highway Leadership Shift At Allison Transmission Holdings (ALSN) Has Changed Its Investment Story

Allison Transmission Holdings has reorganized into two business units, Allison Transmission and Allison Off-Highway Drive & Motion Systems, with Fred Bohley and newly appointed executive Craig Price leading the units and reporting to CEO David Graziosi. The hiring of Price from Dana’s Off-Highway business, alongside his long tenure in purchasing and supplier development, signals a push to tightly manage costs and extract efficiencies from the recently acquired operations. Next, we’ll examine...
NYSE:SHO
NYSE:SHOHotel and Resort REITs

Assessing Sunstone Hotel Investors (SHO) Valuation After Baird Downgrade And Steady Dividend Yield

Baird’s downgrade of Sunstone Hotel Investors (SHO) from Outperform to Neutral puts fresh attention on the REIT’s positioning versus peers, particularly given its consistent dividend history and current 3.82% yield. See our latest analysis for Sunstone Hotel Investors. The Baird downgrade comes after a mixed run for the stock, with a 1-day share price return of 1.08% and a 30-day share price return of 1.30%, set against a 1-year total shareholder return decline of 16.11%. Taken together, this...
NasdaqGM:ARCT
NasdaqGM:ARCTBiotechs

Does Arcturus Therapeutics (ARCT) JPM Conference Spotlight Clarify Its Long-Term Platform Credibility?

Arcturus Therapeutics Holdings Inc. recently presented at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at the Westin St. Francis Hotel in San Francisco, with Founder, President, CEO and Director Joseph E. Payne speaking. This high-profile conference appearance offered Arcturus a platform to showcase its pipeline and corporate story to a concentrated audience of healthcare-focused investors and industry peers. With this conference spotlight and recent share price...
NasdaqGS:MASI
NasdaqGS:MASIMedical Equipment

How Investors May Respond To Masimo (MASI) Record Hospital Contracts And Preliminary 2025 Revenue Growth

Masimo Corporation has already presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and released preliminary fourth-quarter and full-year 2025 results indicating approximately 12% quarterly and 9% annual revenue growth. Management also highlighted a record level of incremental contract value from new and expanded hospital agreements, underscoring the importance of long-term customer relationships to the business. We’ll now examine how the record incremental...
OTCPK:HONT
OTCPK:HONTBanks

Honat Bancorp (OTCPK:HONT) Earnings Growth Outpaces Long Run Trend And Fuels Margin Expansion Narrative

Honat Bancorp (HONT) has put another solid quarter on the board, with Q2 2025 revenue of US$11.4 million and basic EPS of US$2.57 feeding into trailing twelve month EPS of US$10.46 on revenue of US$44.6 million and net income of US$15.0 million. Over the past year, the company has seen revenue move from US$38.8 million to US$44.6 million on a trailing basis, while EPS climbed from US$8.33 to US$10.46, and earnings growth of 19% has supported a net profit margin of 33.5% compared with 31.2% a...
NYSE:FIS
NYSE:FISDiversified Financial

Is Fidelity National Information Services (FIS) Price Weakness Creating A Long Term Opportunity?

If you are wondering whether Fidelity National Information Services is priced attractively right now, you are not alone. Many investors are asking if the current share price lines up with the company’s underlying value. The stock recently closed at US$64.23, with returns of a 4.2% decline over 7 days, a 4.3% decline over 30 days, a 2.1% decline year to date, a 16.2% decline over 1 year, and a 44.0% decline over 5 years, which may influence how you think about its potential and its...
NasdaqGS:IMVT
NasdaqGS:IMVTBiotechs

Assessing Immunovant (IMVT) Valuation As Share Momentum Meets High Price To Book Multiple

Immunovant (IMVT) has been drawing attention after recent share moves that contrast a loss-making profile with fast annual growth in revenue and net income metrics, raising questions about how investors are weighing its clinical-stage risks. See our latest analysis for Immunovant. At a share price of $26.18, Immunovant’s recent 1 day share price return of 1.43% and 90 day share price return of 46.01% sit alongside a 1 year total shareholder return of 14.42% and 3 year total shareholder return...
NYSE:SJM
NYSE:SJMFood

Is J. M. Smucker (SJM) Pricing Reflect Its Long Term Cash Flow Potential

If you are wondering whether J. M. Smucker's current share price fairly reflects its long term value, you are not alone. This article is built to unpack exactly that question. The stock last closed at US$101.61, with returns of 5.9% over the past 7 days, 5.2% year to date and 3.8% over the last year. The 3 year return sits at a 27.3% decline and the 5 year return at 3.7%. Recent coverage around J. M. Smucker has focused on its position in packaged foods and consumer staples, as investors...